JEISYS MEDICAL INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10,590 KRW | -0.09% |
|
+0.86% | +0.95% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 183B 134M | Sales 2025 * | 210B 154M | Capitalization | 799B 584M |
|---|---|---|---|---|---|
| Net income 2024 * | 45B 32.9M | Net income 2025 * | 51B 37.28M | EV / Sales 2024 * | 4.1 x |
| Net cash position 2024 * | 48.85B 35.71M | Net cash position 2025 * | 81.53B 59.6M | EV / Sales 2025 * | 3.41 x |
| P/E ratio 2024 * |
19.9
x | P/E ratio 2025 * |
15.8
x | Employees | 231 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 69.08% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.09% | ||
| 1 week | +0.86% | ||
| Current month | +9.97% | ||
| 1 month | +9.18% | ||
| 3 months | +28.05% | ||
| 6 months | -15.55% | ||
| Current year | +0.95% |
1 week
9 570.00
10 920.00
1 month
9 090.0012 650.00
Current year
7 390.0012 650.00
1 year
7 390.0014 500.00
3 years
4 475.0014 500.00
5 years
3 540.0014 500.00
10 years
3 540.0014 500.00
| Managers | Title | Age | Since |
|---|---|---|---|
Jong-Hwan Kim
CEO | Chief Executive Officer | 56 | - |
Bo-Gun Jeong
AUD | Comptroller/Controller/Auditor | 47 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jong-Hwan Kim
CEO | Chief Executive Officer | 56 | - |
Hong-Sik Park
BRD | Director/Board Member | 46 | - |
Ji-Su Park
BRD | Director/Board Member | 52 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 4 M€ | -4.41% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 10,590 | -0.09% | 2,870,772 |
| 24-05-09 | 10,600 | +7.72% | 3,750,853 |
| 24-05-08 | 9,840 | -2.96% | 2,369,540 |
| 24-05-07 | 10,140 | -2.97% | 1,850,182 |
| 24-05-03 | 10,450 | -0.48% | 2,373,977 |
End-of-day quote Korea S.E., May 09, 2024
More quotes
Jeisys Medical Inc, formerly Yuanta 3 Special Purpose Acquisition Co Ltd, a Korea-based company principally engaged in the manufacturing and distribution of medical devices. The Company manufactures and sells skin care medical devices such as ULTRAcel Q+, POTENZA, and other products. In addition, the Company also provides consumables such as cartridges and tips.
Calendar
2024-08-08
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
10,590
KRW
Average target price
14,038
KRW
Spread / Average Target
+32.55%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +0.95% | 583M | |
| +11.73% | 226B | |
| +9.53% | 188B | |
| +14.63% | 137B | |
| +27.47% | 108B | |
| -0.04% | 63.19B | |
| +13.73% | 52.26B | |
| +4.86% | 51B | |
| +7.72% | 43.89B | |
| +7.86% | 38.07B |
- Stock Market
- Equities
- A287410 Stock